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Recent genome-wide association studies (GWAS) of late-onset Alzheimer’s disease (LOAD) have identified single
nucleotide polymorphisms (SNPs) which show significant association at the well-known APOE locus and at nineteen
additional loci. Among the functional, disease-associated variants at these loci, missense variants are particularly
important because they can be readily investigated in model systems to search for novel therapeutic targets. It
is now possible to perform a low-cost search for these “actionable” variants by genotyping the missense variants
at known LOAD loci already cataloged on the Exome Variant Server (EVS). In this proof-of-principle study designed
to explore the efficacy of this approach, we analyzed three rare EVS variants in APOE, p.L28P, p.R145C and p.V236E, in
our case control series of 9114 subjects. p.R145C proved to be too rare to analyze effectively. The minor allele of p.L28P,
which was in complete linkage disequilibrium (D’ = 1) with the far more common APOE ε4 allele, showed no
association with LOAD (P = 0.75) independent of the APOE ε4 allele. p.V236E was significantly associated with
a marked reduction in risk of LOAD (P = 7.5×10−05; OR = 0.10, 0.03 to 0.45). The minor allele of p.V236E, which
was in complete linkage disequilibrium (D’ = 1) with the common APOE ε3 allele, identifies a novel LOAD-associated
haplotype (APOE ε3b) which is associated with decreased risk of LOAD independent of the more abundant APOE ε2, ε3
and ε4 haplotypes. Follow-up studies will be important to confirm the significance of this association and to better define
its odds ratio. The ApoE p.V236E substitution is the first disease-associated change located in the lipid-binding, C-terminal
domain of the protein. Thus our study (i) identifies a novel APOE missense variant which may profitably be studied to
better understand how ApoE function may be modified to reduce risk of LOAD and (ii) indicates that analysis of
protein-altering variants cataloged on the EVS can be a cost-effective way to identify actionable functional variants
at recently discovered LOAD loci.Introduction
The international effort to catalog common variants [minor
allele frequency (MAF) > 5%] in the human genome (Hap-
Map Project [1]) paved the way for genome-wide associ-
ation studies (GWAS), which have proven to be a powerful
tool for understanding the genetics of complex diseases.
GWAS of late-onset Alzheimer’s disease (LOAD), a genet-
ically complex disease with an estimated 60-80% heritability
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nineteen additional loci. The identification of these com-
mon GWAS SNPs that replicably associate with LOAD is a
significant breakthrough, but it is important to recognize
that these SNPs do not identify the functional disease-
modifying variant(s) to which they are linked, and they do
not fully account for LOAD heritability. It is now clear that
at least some of this missing heritability is accounted for by
rare variants with large effect size. This is well-illustrated
by the recently discovered rare, LOAD-associated missense
variants in the TREM2 gene [3,4]. Importantly, this locus
was not detected using the GWAS approach because the
TREM2 LOAD-associated variants, which are not included
in GWAS genotyping arrays, are too rare to be detected atl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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GWAS SNPs to which they are linked.
Among the functional variants at GWAS loci, those
that alter proteins are particularly important because
they can readily be investigated in model systems to
search for novel therapeutic targets. The Exome Variant
Server (EVS, http://evs.gs.washington.edu/EVS/) catalogs
whole exome sequencing of 4300 unrelated European
Americans, a series large enough to detect virtually all
exonic variants with a minor allele frequency (MAF) of
0.1% (1/1000) or more. Thus expensive resequencing is
no longer required to discover such variants, and it is
now possible to perform a meaningful, low-cost search
for “actionable” variants with MAF > 0.1% by genotyping
protein-altering variants cataloged on the EVS in large
European American case-control series. To evaluate the
utility of this approach, we searched the EVS for protein-
altering APOE variants with MAF > 0.1% and found just
two, p.L28P (0.17%) and p.V236E (0.12%) in European
Americans. Both were analyzed in our large European
American case control series of 4128 LOAD subjects and
4986 non-demented controls (Table 1). In addition we an-
alyzed one extremely rare variant, p.R145C (0.026%), that
did have a MAF > 1% in African Americans.
Result
In this proof of principle study, we used our large LOAD
case-control series (Table 1) to analyze three missense
variants in the APOE gene that were mined from the
EVS database: rs769452 (T/c, p.L28P), rs769455 (C/t, p.
R145C) and rs199768005 (T/c, p.V236E). Comparison of
EVS European Americans with the control subjects in
our series showed no significant difference in the
MAFs for rs769452 (P = 0.27), rs769455 (P = 0.46) or
rs199768005 (P = 0.075).
rs769455 (ApoE p.R145C) was successfully genotyped
in 3955 AD cases and 4590 controls. With only 4 het-
erozygotes in the AD cases, 1 in the control group, and
no homozygotes, p.R145C was too rare to analyze effect-
ively as expected from its EVS frequency. Analysis by a
Fisher’s exact test yielded an odds ratio (OR) and 95%Table 1 Sample demographics for case-control series
Series n (%) Mean AAD ± SD (Years
AD CON AD CON
Jacksonville 1020 (41.2) 1453 (58.8) 77.7 (6.46) 79.5 (7
Rochester 600 (19.9) 2409 (80.1) 80 (7.72) 78.3 (5
Poland 250 (100) 0 (0) 74.4 (5.19) NA (N
Norway 345 (38.5) 552 (61.5) 80.2 (7.25) 75.4 (6
NCRAD 702 (77.1) 209 (22.9) 75.2 (6.76) 78.3 (8
Autopsy* 1211 (76.9) 363 (23.1) 81.4 (8.56) 75.9 (8
Total 4128 (45.3) 4986 (54.7) 78.7 (7.76) 78.2 (6
*Autopsy controls unlike the clinical controls, who were neurologically normal, incluconfidence interval (95% CI) of 4.64 (0.52 to 41.56) with
a p value of 0.13. In African Americans, the MAF for
rs769455 on the EVS is 1.39% as compared to 0.026% in
European Americans, so we evaluated this variant in our
African American LOAD case control series of 168
LOAD patients and 333 non-demented control subjects.
There were 9 heterozygotes in the AD cases compared
to 17 in the control group and no homozygotes. A chi-
square test showed no evidence of allelic association
with LOAD (P = 0.91: OR = 1.05, 0.46 to 2.38), but the
small series tested has relatively little statistical power as
an OR of approximately 3.3 is required for 80% power to
detect association at α = 0.05. Analysis in additional
case-control studies is clearly needed to evaluate the as-
sociation of this rare variant with LOAD.
rs769452 (ApoE p.L28P) was successfully genotyped in
2996 late-onset AD cases and 3951 control samples.
There were 36 heterozygotes in the AD cases compared
to 20 in the control group and no homozygotes. Analysis
of rs769452 by a Fisher’s exact test showed significant
(P = 1.6×10−03) association with increased risk of LOAD
(OR = 2.39, 1.38 to 4.37). In African Americans (AA), the
MAF for rs769452 on the EVS is 0.023% as compared to
0.17% in European Americans, so this variant was not ge-
notyped in our small AA series.
rs199768005 (ApoE p.V236E) was successfully geno-
typed in 4128 late-onset AD cases and 4986 control
samples. There were 2 heterozygotes in the AD cases
compared to 23 in the control group and no homozy-
gotes. Confirmatory genotyping using a custom TaqMan
assay was 100% concordant. Analysis of rs199768005 by
a Fisher’s exact test showed significant (P = 7.5×10−05)
association with markedly reduced risk of LOAD (OR =
0.10, 0.03 to 0.45). rs199768005 was not genotyped in
our small AA series, as its minor allele was never de-
tected in the much larger set of 2203 EVS AA subjects.
The well-known APOE ε2, ε3, and ε4 haplotypes are
formed by two APOE missense SNPs, rs429358 (T/c, p.
C112R) and rs7412 (C/t, p.R158C), as shown in Table 2.
The minor alleles of rs429358 and rs7412 tag the ε4 and
ε2 haplotypes respectively; the ε3 haplotype has major) Females (%) ε4+ Subjects (%)
AD CON AD CON
.86) 623 (61.1) 838 (57.7) 653 (64.0) 338 (23.3)
.56) 363 (60.5) 1294 (53.7) 328 (54.7) 571 (23.7)
A) 156 (62.4) NA (NA) 139 (55.6) NA (NA)
.73) 241 (69.9) 330 (59.8) 217 (62.9) 132 (23.9)
.88) 455 (64.8) 129 (61.7) 551 (78.5) 34 (16.3)
.14) 695 (57.4) 155 (42.7) 744 (61.4) 98 (27.0)
.91) 2533 (61.4) 2746 (55.1) 2632 (63.8) 1155 (23.2)
de some non-AD degenerative disorders.
Table 2 APOE Haplotypes formed by three variants and their association with AD
APOE
Haplotype†
rs429358 rs7412 rs199768005 rs769452 Minor allele
frequency (%)
Logistic regression*
p.C112R p.R158C p.V236E p.L28P Univariate Multivariate
Base AA Base AA Base AA Base AA AD CON OR P OR P
ε2 allele T Cys t Cys T Val T Leu 3.15% 8.50% 0.35 (0.30-0.40) <2x10−16 0.46 (0.38-0.54) <2x10−16
ε3a allele T Cys C Arg T Val T Leu 58.0% 79.0% 0.35 (0.32-0.37) <2x10−16 1.00 (REF) REF
ε3b allele T Cys C Arg c Glu T Leu 0.024% 0.23% 0.11 (0.02-0.36) 2.32x10−03 0.10 (0.02-0.35) 2.16x10−03
ε4a allele C Arg C Arg T Val T Leu 37.4% 12.3% 5.00 (4.52-5.50) <2x10−16 4.80 (4.35-5.30) <2x10−16
ε4b allele C Arg C Arg T Val c Pro 0.62% 0.26% 2.49 (1.45-4.41) 1.17x10−03 0.91 (0.51-1.66) 0.75
Alleles in uppercase denote a major allele, alleles in lower case denote a minor allele.
*Logistic regression models corrected for sex and age-at-diagnosis, and assume an additive effect.
† Haplotype phasing showed that the minor allele of rs199768005 (p.V236E) is in phase (D’ = 1) with the major alleles at rs429358 and rs7412, indicating that it
occurs on the ε3 backbone thereby subdividing the ε3 haplotype into APOE ε3b (minor allele of rs199768005) and APOE ε3a (major allele of rs199768005).
rs769452 (p.L28P) subdivides ε4 into APOE ε4b (minor allele of rs769452) and APOE ε4a (major allele of rs769452).
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minor allele of rs199768005 (p.V236E) is in phase (D’ = 1)
with APOE ε3 (major alleles at rs429358 and rs7412) and
that the minor allele of rs769452 (ApoE p.L28P) is in
phase with APOE ε4 (minor allele at rs429358, major at
rs7412). Thus p.V236E occurs on the ε3 backbone subdiv-
iding the ε3 haplotype into APOE ε3b (minor allele of
rs199768005) and APOE ε3a (major allele of rs199768005)
whereas p.L28P subdivides ε4 into APOE ε4b (minor allele
of rs769452) and APOE ε4a (major allele of rs769452), as
shown in Table 2. Univariate logistic regression using an
additive model with sex and age at diagnosis as covar-
iates gave results for the ε3b (OR = 0.11, 0.02 to 0.36;
P = 2.32×10−03) and e4b (OR = 2.49, 1.45 to 4.41; P =
1.17×10−3) haplotypes which were essentially identical
to the Fisher exact results for the missense variants
that tag them. As expected, univariate logistic regres-
sion showed that the ε4 allele was associated with sig-
nificant, markedly increased risk of AD and that the
ε2 and ε3a alleles were associated with significant,
markedly reduced risk. To determine whether APOE
ε3b or ε4b are significantly associated with LOAD in-
dependent of the ε2, ε3, and ε4 alleles, we performed
multivariate logistic regression using a model that in-
cluded not only sex and age at diagnosis as covariates
but also the APOE ε4 and ε2 alleles, with ε3a as refer-
ent (Table 2). When the APOE ε4 and ε2 alleles were
included as covariates, the ε4b showed no association
(P = 0.75), indicating that the minor allele of p.L28P
does not significantly modify the risk associated with
APOE ε4 when it is present on that haplotype
(Table 2). Importantly, the ε3b allele contributed sig-
nificantly (OR = 0.10, 0.02 to 0.35; P = 2.16×10−3) to a
model that included APOE ε2 and ε4 as covariates
with APOE ε3a as referent. Thus, compared to APOE
ε3a, APOE ε3b (ApoE p.236E) is associated with a sig-
nificantly decreased risk of AD that is independent of
the ε2 and ε4 alleles.Discussion
Our results show that ApoE p.V236E occurs on the
APOE ε3 backbone creating a rare APOE ε3b haplotype,
which is significantly associated with LOAD independ-
ent of the APOE ε2, ε3, and ε4 alleles. Comparison of
the 95% CI for APOE ε3b (OR = 0.10, 0.02 to 0.35) with
that for APOE ε2 (OR = 0.46, 0.38 to 0.54), indicates
that, in our series, the ε3b allele reduced risk of AD as
much or more than the APOE ε2 allele (Table 2, Multi-
variate Logistic Regression). In this regard, it is worth
noting that, of the 2 LOAD patients carrying p.V236E,
one developed dementia at an advanced age (98 yrs,
APOE ε3a/ε3b genotype) and the other, who was diag-
nosed at 68, also carried an ε4 allele (APOE ε3b/ε4 geno-
type), which likely counters the protection afforded by p.
V236E. The 23 non-demented control carriers included
7 with ages of 64-88 years with ε3b/ε4 genotypes, 14
with ages of 68-91 with ε3b/ε3a genotypes, and 2 with
ages of 68 and 92 with ε3b /ε2 genotypes. To verify the
significance of the association observed in our series and
to improve the OR estimate for p.V236E, replication in a
similarly large series will be important, ideally a series
with GWAS genotypes that can be used to adjust for the
potentially confounding effect of population stratifica-
tion. If APOE ε2 and ε3b act similarly, as seems likely,
then analysis of the functional effects of ε2 as compared
to the novel ε3b allele identified here could provide
insight into the common or distinct mechanism whereby
they reduce risk of LOAD.
In three previous studies [5-7], rs769452 (ApoE p.L28P)
was genotyped in a total of 2630 subjects (1329 AD/1401
Control: 1118/1123 [5], 117/121 [6], 93/157 [7]. These
studies also found that ApoE p.L28P occurs on the APOE
ε4 backbone. The risk associated with the minor allele of
rs769452, which tags the rare APOE ε4b allele, appeared
to be greater than the risk of APOE ε4 in two of these
studies [5,7] but less in the other study [6]. When the re-
sults from these previous series were combined with those
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was 4.31 (3.96 to 4.70) as compared to 4.04 (2.74 to 6.00)
when APOE ε4b was compared to the same referent
group. Thus the combined results from all series, like
those from our series alone (Table 2), indicate that the
minor allele of p.L28P does not substantially modify the
risk associated with APOE ε4 when it is present on that
haplotype. Replication in additional large series will be im-
portant to confirm this finding.
ApoE is a 299 amino acid long protein with a highly
hydrophobic lipid binding domain in the C-terminal re-
gion, and a receptor binding domain in the N-terminal
region. Bridged by a protease sensitive hinge region, the
N- and C-terminal domains appear to interact when
ApoE is delipidated, preventing lipoprotein receptor
docking and internalization of unlipidated ApoE [8]. The
two missense variants that create the APOE ε2 (p.C112R)
and APOE ε4 (p.R158C) alleles both alter amino acids in
the N-terminal region, which may interfere with receptor
binding. The missense variant (p.V236E) that creates the
APOE ε3b allele is the first LOAD-associated variant to
alter a C-terminal amino acid [9]. The protein encoded
by APOE ε3b has previously been described as APOE*2
[10] because upon isoelectric focusing it migrates simi-
larly to the APOE2 protein encoded by the APOE ε2
allele. Studies of individuals carrying p.V236E have
found no lipoprotein abnormalities [11]. Pathogenicity
prediction using SIFT and PolyPhen-2 both suggest p.
V236E is damaging, substituting a nonpolar, hydropho-
bic valine for the negatively charged, hydrophilic glu-
tamic acid. Position 236 is proximal to the lipid
binding domain (244-272) and interestingly it is lo-
cated within a region believed to be important for
ApoE oligomerization (230-243) [12]. The substitution
of a hydrophobic valine for an ionic glutamic acid is
consistent with p.V236E altering the lipid binding
property of ApoE, or affecting aggregation. Addition-
ally, in light of the interaction between ApoE N- and
C-terminal domains, p.V236E could alter ApoE folding
and receptor binding. We are currently investigating
these possibilities.
In this proof of principle study, we searched the EVS
for protein-altering APOE variants with MAF > 0.1% and
found just two, p.L28P (0.17%) and p.V236E (0.12%).
Both were tested for association with LOAD in our large
case-control series, and one (p.V236E) was significantly
associated with markedly decreased risk of LOAD, inde-
pendent of the APOE ε2, ε3, and ε4 alleles. It will now
be important to determine if this same cost-effective ap-
proach can be used to identify additional LOAD-
associated, protein altering variants in genes at any of
the recently discovered LOAD loci that might profitably
be investigated to identify novel therapeutic targets for
AD.Materials and methods
Case-control subjects
Demographic information on the LOAD patients and
non-demented control subjects that were analyzed is
shown in Table 1. Approval was obtained from the ethics
committee or institutional review board of each institu-
tion responsible for the ascertainment and collection of
samples. Written informed consent was obtained for all
individuals who participated in this study.
The Mayo case-control series consists of European
Americans ascertained at the Mayo Clinic Jacksonville,
Mayo Clinic Rochester, and in the Mayo Clinic autopsy-
confirmed samples (Autopsy in Table 1). Additional
Caucasian subjects from the United States were obtained
through the National Cell Repository for Alzheimer’s
Disease (NCRAD in Table 1), and European Caucasian
subjects were obtained from Norway [13] and Poland
[14,15]. All subjects in the Mayo clinical case-control
series were diagnosed by a neurologist at the Mayo Clinic
in Jacksonville, Florida, or Rochester, Minnesota. The neur-
ologist confirmed a Clinical Dementia Rating score of 0 for
all Jacksonville and Rochester subjects enrolled as controls;
cases had diagnoses of possible or probable AD made ac-
cording to NINCDS-ADRDA criteria [16]. Clinical LOAD
cases and controls in the NCRAD, Polish, and Norwegian
were ascertained similarly. In the autopsy-confirmed series,
all brains were evaluated by Dr. Dennis Dickson and came
from the brain bank he maintains at the Mayo Clinic in
Jacksonville, FL. In the Autopsy series the diagnosis of def-
inite AD was also made according to NINCDS-ADRDA
criteria. Only samples with an age-at-diagnosis (AAD)
above 60 years, with sex and APOE covariates (ε2, ε3, ε4 al-
leles) available, were included in this study.
Nomenclature
To conform to most of the literature on ApoE, our num-
bering of ApoE residues begins with the first amino acid
that remains after removal of the 18 amino acid leader se-
quence. This is different from EVS numbering which be-
gins with the first amino acid in the leader sequence [17].
The protein encoded by the APOE ε3b allele, which is cre-
ated by the minor allele of p.V236E (see Table 2), has pre-
viously been described as APOE*2 [10,11] because upon
isoelectric focusing it migrates similarly to the APOE2
protein encoded by APOE ε2 allele.
Genotyping
APOE missense variants resulting in p.L28P (rs769452),
p.R145C (rs769455) and p.V236E (rs199768005) were
genotyped using SEQUENOM’s MassArray iPLEX tech-
nology (SEQUENOM Inc, San Diego, CA, USA). SEQUE-
NOM’s Typer Analyzer 4.0 was used to conduct off
machine processing and genotype calling. Confirmatory
genotyping of p.V236E was carried out using a custom
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tection System with 384-Well Block Module (Applied
Biosytems, California, USA). TaqMan assays were also
employed to genotype the APOE missense variants
resulting in p.R158C (rs7412) and p.C112R (rs429358) in
order to identify the well-known APOE ε2, ε3, and ε4 al-
leles. Cluster calling was carried out using SDS software
v2.2.3 (Applied Biosytems, California, USA). All Sequenom
and TaqMan probe sequences are available on request.
Statistical analysis
Analysis of control subjects using PLINK [18] (http://
pngu.mgh.harvard.edu/~purcell/plink/), showed that all
variants were in Hardy Weinberg equilibrium (P > 0.80).
Allelic association was evaluated using Fisher’s exact
method in PLINK. Haplotypic analysis was performed
using the haplo.stats package in the R programming lan-
guage (v2.14.1). Logistic regression was carried out adjust-
ing for sex and age at diagnosis.
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